Add to ORKGThe relationship between treatment with statins and vascular diseases is complex and still not well established. This narrative review examined the existing literature in order to find out how treatment with statins and vascular diseases are linked, with special focus on the processes and underlying pharmacological mechanisms leading to decrease in the incidence of vascular diseases.egységes, osztatlanáltalános orvosango
During the past 2 decades, atherosclerosis and its clinical sequelae have increasingly been recogniz...
Peripheral arterial disease (PAD) of the lower limbs is the third most important site of atheroscler...
Peripheral arterial disease (PAD) of the lower limbs is the third most important site of atheroscler...
Copyright © 2003 Elsevier Ltd. All rights reserved.Background: Recent publications have highlighted ...
Vascular oxidative stress is a key feature of atherogenesis, and targeting vascular redox signalling...
Hahnemann considered the secondary action of medicines to be a law of nature and reviewed the condit...
Hahnemann considered the secondary action of medicines to be a law of nature and reviewed the condit...
3-hydroxy-3-methylglutaryl coenzyme A reductase (HMG CoA-reductase) inhibitors, otherwise known as s...
HMG CoA reductase inhibitors (statins) have become the cornerstone in prevention of atherosclerotic ...
Statins inhibit HMG-CoA reductase by competitively inhibiting the active site of the enzyme, thus pr...
The use of statins has recently attracted the attention of clinicians. Indeed, statins are probably ...
Atherosclerosis develops over the course of 50 years. It is a generally asymptomatic process that be...
AbstractSignificant advances in the management of cardiovascular disease have been made possible by ...
Endothelial dysfunction is a natural process associated with aging. Prevention of endothelial dysfun...
Chronic inflammation enhances the detrimental role of dyslipidaemia during atherogenesis. Statins ar...
During the past 2 decades, atherosclerosis and its clinical sequelae have increasingly been recogniz...
Peripheral arterial disease (PAD) of the lower limbs is the third most important site of atheroscler...
Peripheral arterial disease (PAD) of the lower limbs is the third most important site of atheroscler...
Copyright © 2003 Elsevier Ltd. All rights reserved.Background: Recent publications have highlighted ...
Vascular oxidative stress is a key feature of atherogenesis, and targeting vascular redox signalling...
Hahnemann considered the secondary action of medicines to be a law of nature and reviewed the condit...
Hahnemann considered the secondary action of medicines to be a law of nature and reviewed the condit...
3-hydroxy-3-methylglutaryl coenzyme A reductase (HMG CoA-reductase) inhibitors, otherwise known as s...
HMG CoA reductase inhibitors (statins) have become the cornerstone in prevention of atherosclerotic ...
Statins inhibit HMG-CoA reductase by competitively inhibiting the active site of the enzyme, thus pr...
The use of statins has recently attracted the attention of clinicians. Indeed, statins are probably ...
Atherosclerosis develops over the course of 50 years. It is a generally asymptomatic process that be...
AbstractSignificant advances in the management of cardiovascular disease have been made possible by ...
Endothelial dysfunction is a natural process associated with aging. Prevention of endothelial dysfun...
Chronic inflammation enhances the detrimental role of dyslipidaemia during atherogenesis. Statins ar...
During the past 2 decades, atherosclerosis and its clinical sequelae have increasingly been recogniz...
Peripheral arterial disease (PAD) of the lower limbs is the third most important site of atheroscler...
Peripheral arterial disease (PAD) of the lower limbs is the third most important site of atheroscler...